Targeted Oncology Staff

Andrew M. Evens, DO, MSc, considered the data supporting brentuximab vedotin with chemotherapy for the treatment of a patient with peripheral T-cell lymphoma.

An accelerated approval was granted by the FDA to sacituzumab govitecan for the treatment of patients with locally advanced or metastatic urothelial cancer who previously received a platinum-containing chemotherapy and either a PD-1 or PD-L1 inhibitor.

During a virtual Targeted Oncology Case-Based Roundtable event, Kartik Konduri, MD, discussed the case of a 58-year-old patients with small cell lung cancer.

Thomas Hutson, DO, PharmD, discussed the case of a 66-year-old patient with bladder cancer during a virtual Targeted Oncology Case-Based Roundtable event.

Vivek Subbiah, MD, explored the treatment options for RET-fusion positive non–small cell lung cancer during a virtual Targeted Oncology Case-Based Roundtable event.

During a virtual Targeted Oncology Case-Based Roundtable event, Toni K. Choueiri, MD, lead a debate with a group of peers on second-line therapy options for patients with renal cell carcinoma.

Schlafen-11 expression may serve as a predictive biomarker for response to select treatments in patients with small cell lung cancer.

Integrating afatinib into standard-of-care chemoradiation with or without surgery demonstrated encouraging efficacy, feasibility, and safety results in patients with stage III EGFR-mutation positive non–small cell lung cancer.

Joshi Alumkal, MD assessed the available checkpoint inhibitors for the treatment of mutated metastatic castration-resistant prostate cancer.

During a virtual Targeted Oncology Case-Based Roundtable event, Marcia S. Brose, MD, PhD, led a peer discussion about frontline treatment of a patient with differentiated thyroid cancer.

Neratinib demonstrated single-agent efficacy with significant response and survival rates in tyrosine kinase inhibitor-refractory patients with non– small cell lung cancer whose tumors harbor EGFR exon 18 mutations.

Assessing prognosis is an important step prior to treatment selection for a patient with classic Hodgkin lymphoma, explained Joseph Michael Tuscano, MD. Other steps aid in the treatment and management of toxicity.

Alicia K. Morgans, MD, MPH, associate professor of Medicine, Feinberg School of Medicine, Northwestern University, reviewed the clinical trial results for multiple hormonal therapies intended to treat prostate cancer. She explained that many of them show similar outcomes.

Thomas G. Martin, MD discussed the case of a patient with newly-diagnosed multiple myeloma during a virtual Targeted Oncology Case-Based Roundtable event.

A number of clinical trials have provided evidence of efficacy of combination regimens for the treatment of RET-mutant medullary thyroid cancer. During a virtual Targeted Oncology Case-based Roundtable event, Lori Wirth, MD, discussed the options for a 58-year-old man with RET-mutant medullary thyroid cancer.

During a virtually held Targeted Oncology Case-Based Roundable event, Meghan Mooradian, MD, discussed the case of a 63-year-old patient diagnosed with non–small cell lung cancer.

Hedgehog inhibitors are becoming more widely used for Basal cell carcinoma. Two experts, Shailender Bhatia, MD and Paul T. Nghiem, MD, PhD discussed the reality of hedgehog inhibitor use in practice during a virtual Targeted Oncology Case-Based Roundtable event.

During a virtual Targeted Oncology Case-Based Roundtable event, Eleni Efstathiou, MD, PhD, discussed the case of a 75-year-old patients with metastatic castration-resistant prostate cancer.

Jessica Donnington, MD, led a discussion with a group of peers regarding treatment of non–small cell lung cancer during a virtual Targeted Oncology Case-Based Roundtable event.

During a virtual Targeted Oncology Case-Based Roundtable event, Daniel O. Persky, MD, reviewed the case of a 61-year-old patient with chronic lymphocytic leukemia.

During a virtual Targeted Oncology Case-Based Roundtable, Ajai Chari, MD. a professor of Medicine, Hematology, and Medical Oncology at the Icahn School of Medicine at Mount Sinai in New York, NY, discussed the case of a 72-year-old patient with multiple myeloma.

During a virtual Targeted Oncology Case-Based Roundtable event, Anish B. Parikh, MD, discussed front-line treatment options for metastatic urothelial cancer as well as the data supporting avelumab maintenance.

Corey J. Langer, MD, discusses treatment options for a patient with non–small cell lung cancer based on the clinical trial research.

During a Targeted Oncology virtual Case-Based Roundtable event, William K. Oh, MD, reviewed the data from the CARD trial as he shared the case of a 75-year-old man with metastatic castration-resistant prostate cancer (mCRPC) with a group of peers.

Pierluigi Porcu, MD, explained how the combination of brentuximab vedotin plus chemotherapy works in in frontline setting of Hodgkin lymphoma during a virtual Targeted Oncology Case-Based Roundtable event.

David Dingli, MD, PhD, professor of Medicine at the Mayo Clinic, reviews the combination therapies available for the treatment of multiple myeloma in a patient who is 72-years-old and transplant-ineligible.

Tulio E. Rodriguez, MD, weighs the various treatment options available for a patient with multiple myeloma.

During a Targeted Oncology Case-Based Peer Perspective event, Kathleen Moore, MD, discussed the combination of bevacizumab and olaparib as treatment of ovarian cancer.

During a Targeted Oncology Case-Based Peer Perspectives event, Ulka Nitin Vaishampayan, MBBS, FAB, discussed the case of a 72-year-old patients with metastatic castration-resistant prostate cancer.

For the treatment of patients with lung cancer and low PD-L1 expression, immunotherapy-based combinations have been shown effective through clinical trial research. Stephen Liu, MD, reviewed the studies during a Targeted Oncology Case-Based Peer Perspectives virtual event.